Stay updated with breaking news from Daniel Vitt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Population Caused by Unexpected Interference Between Vidofludimus Calcium and...
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
Immunic Inc. (NASDAQ:NASDAQ:IMUX) Q1 2022 Earnings Conference Call May 10, 2022, 8:00 AM ET Company Participants Daniel Vitt – Chief Executive officer, President & Director Glenn Whaley...
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
Issuer: Immunic, Inc. / Key word(s): Study Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease 05.05.2022 / 12:30 The issuer is solely responsible for the content of this announcement. Immunic Announces Start of Patient Cohorts in Its Phase 1 Cli...